Clinical Safety Data Management: Definitions and Standards for Expedited Reporting
The ICH guideline establishing the definitions (serious, unexpected, adverse reaction) and standards for expedited safety reporting during clinical development. E2A defines the SUSAR concept and the 7-day (fatal/life-threatening) and 15-day expedited reporting timelines that regulators worldwide adopted.
What this does not cover
stated in the document's own scope- Covers expedited reporting during clinical development; routine periodic and post-marketing reporting are the subject of E2C and E2D.
- Defines the terms and timelines but not the electronic transmission format — that is ICH E2B.
- Sets safety-reporting standards, not the coding dictionary used to classify the events — that is MedDRA.
Always verify against the current published text before relying on it for a submission or inspection.
Overview
ICH E2A is the harmonised guideline that put a shared vocabulary and a shared clock under clinical safety reporting. It fixes the definitions that everything downstream depends on — what counts as an adverse event, an adverse drug reaction, a serious event, and an unexpected reaction — and then sets the standards for expedited reporting of the ones that matter during clinical development. The concept practitioners now call a SUSAR (a suspected, unexpected, serious adverse reaction) traces to these definitions, and the reporting timelines it introduced became the template regulators built their own rules around.
Scope & applicability
Safety data management for investigational products during clinical trials in ICH regions. Complemented by E2B (transmission), E2D (post-approval definitions), and E2F (DSUR).
Legal basis & how it acquires force
E2A is an ICH guideline in the Efficacy (E) series, finalised at Step 4 in October 1994. An ICH guideline is not itself law; it acquires force when each region implements it. In the EU the E2A principles live in the Clinical Trials Regulation and the GVP modules; in the United States the expedited IND safety-reporting obligations sit in 21 CFR 312.32; in Japan they are given effect through MHLW notifications. So a sponsor complies with the regional instrument, and E2A is the common text those instruments were harmonised to.
Document structure
| Part | Covers |
|---|---|
| Definitions | Adverse event, adverse drug reaction, serious, and unexpected — the terms the rest of the guideline turns on |
| Standards for expedited reporting | Which cases require expedited reporting and the circumstances that trigger it |
| Reporting time frames | The 7-day (fatal or life-threatening) and 15-day (other serious, unexpected) clocks |
| How to report | Minimum information for a report and the managing of blinded therapy cases |
| Post-study and other issues | Events after study completion and reporting to investigators and ethics committees |
Quick reference · Expedited reporting clock
When an individual case must reach regulators during clinical development.
| Case | Initial report | Follow-up |
|---|---|---|
| Fatal or life-threatening, serious, unexpected adverse reaction | 7 calendar days | Complete report within 8 further calendar days |
| Other serious, unexpected adverse reaction | 15 calendar days | As new information becomes available |
“Serious” = death, life-threatening, hospitalisation (initial or prolonged), persistent or significant disability/incapacity, or a congenital anomaly/birth defect. “Unexpected” = not consistent with the reference safety information (e.g. the Investigator’s Brochure). US IND safety reports codify the same 7- and 15-day clocks in 21 CFR 312.32.
Source: ICH E2A, expedited reporting standards. Verify against the current text before relying on it for a submission.
Key requirements
- Apply consistent definitions of serious, unexpected, and related adverse events
- Expedite SUSAR reports within 7 or 15 calendar days as applicable
- Assess expectedness against the reference safety information
Implementation tips
- Keep the reference safety information version-controlled — expectedness assessment depends on it
Revision notes
Adopted in 1994; remains the definitional basis for expedited clinical-trial safety reporting, implemented through E2B and regional regulations.
International alignment
E2A is the definitional anchor for the rest of the ICH pharmacovigilance family: E2B specifies the electronic data elements used to transmit these cases, E2D covers the post-approval phase, and MedDRA supplies the coding terminology. Because the FDA, EMA, and MHLW all adopted E2A, the serious/unexpected distinction and the 7- and 15-day clocks are effectively global, even though each region encodes them in its own law.
ICH E2A: frequently asked questions
Quick answers to common questions about ICH E2A.
What is the difference between the 7-day and 15-day reporting timelines in ICH E2A?
E2A sets a 7-calendar-day clock for fatal or life-threatening suspected unexpected serious adverse reactions (with a follow-up report within a further 8 days) and a 15-calendar-day clock for other serious, unexpected reactions. The clock starts when the sponsor first receives the minimum information.
Is ICH E2A legally binding?
Not by itself. E2A is a harmonised guideline; it becomes enforceable through each region’s own law — 21 CFR 312.32 in the US, the Clinical Trials Regulation and GVP in the EU, and MHLW notifications in Japan.
What is a SUSAR and where does the term come from?
A SUSAR is a Suspected, Unexpected, Serious Adverse Reaction. The three qualifiers are exactly the definitions E2A established, which is why the concept is traced back to this guideline even though the acronym is used most in EU legislation.